{"code":"D46.22","type":"code","title":"Refractory anemia with excess of blasts 2","codeAlso":[],"includes":[],"modern_v":"official26","codeFirst":[],"excludes1":["neoplasms of unspecified behavior (D49.-)"],"excludes2":["drug-induced aplastic anemia (D61.1)"],"isBillable":true,"fyEffectivity":{"fy2026":true,"fy2027":true,"billableFy2026":true,"billableFy2027":true},"inclusionTerms":["RAEB 2"],"useAdditionalCode":["code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)"],"clinicalDefinition":"Refractory anemia with excess of blasts 2 is a billable ICD-10-CM diagnosis code (D46.22). Inclusion terms: RAEB 2. Excludes1 (not coded here): neoplasms of unspecified behavior (D49.-). Excludes2 (not included here): drug-induced aplastic anemia (D61.1). Use additional code: code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5).","officialDefinition":"Refractory anemia with excess of blasts 2 is a billable ICD-10-CM diagnosis code (D46.22). Inclusion terms: RAEB 2. Excludes1 (not coded here): neoplasms of unspecified behavior (D49.-). Excludes2 (not included here): drug-induced aplastic anemia (D61.1). Use additional code: code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5).","seventhCharacterInstructions":[],"workflowProtocols":[],"guidelines":{"whenToUse":[],"whenNotToUse":[],"commonBillingMistakes":[],"codeComparisons":[],"documentationChecklist":[]},"domainLandscape":{"summary":"Primary diagnostic domain and clinical landscape evaluation.","keyCategories":[],"diagnosticContinuum":"Progression continuum from acute presentation to resolution."},"children":[],"hierarchy":[],"relatedCodes":[],"relevantCPTCodes":[],"documentationTips":[],"caseStudies":[],"description":"","overview":"","noteProvenance":{"neoplasms of unspecified behavior (D49.-)":"D46","drug-induced aplastic anemia (D61.1)":"D46","code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)":"D46"},"hcc":{"mapped":true,"model":"CMS-HCC V28","paymentYear":"2026","categories":[{"hcc":"17","label":"Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic","family":"Neoplasm","suppresses":[{"hcc":"18","label":"Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid"},{"hcc":"19","label":"Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers"},{"hcc":"20","label":"Lung and Other Severe Cancers"},{"hcc":"21","label":"Lymphoma and Other Cancers"},{"hcc":"22","label":"Bladder, Colorectal, and Other Cancers"},{"hcc":"23","label":"Prostate, Breast, and Other Cancers and Tumors"}]}],"otherModels":[{"model":"CMS-HCC V22","hcc":"46"},{"model":"RxHCC V08","hcc":"19"}]}}